Flow cytometry of cell suspensions from lymph nodes: immunophenotype, DNA content and proliferative rate are strongly correlated with histopathology diagnosis.

1. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998; 129:394-405. 2. Mc Tavish D, Faulds D, Goa KL. Ticlopidine: an updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs 1990; 40:238-59. 3. Page Y, Tardy B, Zeni F, Comtet C, Terrana R, Bertrand JC. Thrombotic thrombocytopenic purpura. 1991; 337:774-6. 4. Bennet CL, Weinberg PD, Rozenberg Ben Droe K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Intern Med 1998; 128:541-4. 5. Ruggenenti P, Remuzzi G. The pathophysiology and management of thrombotic thrombocytopenic purpura. Eur J Haematol 1996; 56:191-207. 6. Moake JL. Moschowitz, multimers, and metalloprotease. N Engl J Med 1998; 339:1629-31. 7. Falezza G, Girelli D, Olivieri O, Gandini G, Corrocher R, De Sandre G. Thrombotic thrombocytopenic purpura developed during ticlopidine therapy. Haematologica 1992; 77:525. 8. Bobbio-Pallavicini E, Gugliotta L, Centurioni R, et al. Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian cooperative group for TTP. Haematologica 1997; 82:429-35. 9. Centurioni R, Candela M, Leoni P, Minnucci ML, Danieli G. Is ticlopidine responsible for thrombotic thrombocytopenic purpura? Haematologica 1992; 78:196-7. 10. Steinbul SR, Wa T, Foody JM, Topol EJ. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting. JAMA 1999; 281:806-10.